Fenoxaprop-ethyl, Flufenpyr-ethyl, Imazapyr, Maleic hydrazide, Pyrazon, Quinclorac, Triflumizole, et al.; Proposed Tolerance and Tolerance Exemption Actions, 6740 [C1-2019-00787]

Download as PDF 6740 Federal Register / Vol. 84, No. 40 / Thursday, February 28, 2019 / Proposed Rules provide oral testimony. The EPA encourages commenters to provide the EPA with a copy of their oral testimony electronically (via email) or in hard copy form. The EPA may ask clarifying questions during the oral presentations, but will not respond to the presentations at that time. Written statements and supporting information submitted during the comment period will be considered with the same weight as oral comments and supporting information presented at the public hearing. Commenters should notify Adrian Gates if they will need specific equipment or if there are other special needs related to providing comments at the hearing. Verbatim transcripts of the hearing and written statements will be included in the docket for the rulemaking. Please note that any updates made to any aspect of the hearing will be posted online at https://www.epa.gov/mats/ proposed-revised-supplemental-findingand-results-residual-risk-andtechnology-review. While the EPA expects the hearing to go forward as set forth above, please monitor our website or contact Adrian Gates at (919) 541– 4860 or gates.adrian@epa.gov to determine if there are any updates. The EPA does not intend to publish a document in the Federal Register announcing updates. The EPA will not provide audiovisual equipment. Commenters should notify Adrian Gates when they pre-register to speak that they will require the service of a translator or special accommodations such as audio description. We may not be able to arrange accommodations without advanced notice. Dated: February 25, 2019. Panagiotis Tsirigotis, Director, Office of Air Quality Planning and Standards. [FR Doc. 2019–03518 Filed 2–27–19; 8:45 am] BILLING CODE 6560–50–P 40 CFR Part 180 [EPA–HQ–OPP–2017–0418; FRL–9970–24] khammond on DSKBBV9HB2PROD with PROPOSALS RIN 2070–ZA16 Fenoxaprop-ethyl, Flufenpyr-ethyl, Imazapyr, Maleic hydrazide, Pyrazon, Quinclorac, Triflumizole, et al.; Proposed Tolerance and Tolerance Exemption Actions Correction In proposed rule document 2019– 00787, appearing on pages 1691 through 17:17 Feb 27, 2019 [FR Doc. C1–2019–00787 Filed 2–27–19; 8:45 am] BILLING CODE 1301–00–D DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services 42 CFR Parts 405, 424, 455, and 457 [CMS–6058–RCN] RIN 0938–AS84 Medicare, Medicaid, and Children’s Health Insurance Programs; Program Integrity Enhancements to the Provider Enrollment Process; Extension of Timeline for Publication of the Final Rule Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Extension of timeline for publication of a final rule. AGENCY: This document announces the extension of the timeline for publication of the ‘‘Medicare, Medicaid, and Children’s Health Insurance Programs; Program Integrity Enhancements to the Provider Enrollment Process’’ final rule. We are issuing this document in accordance with the Social Security Act (the Act), which requires notice to be provided in the Federal Register if there are exceptional circumstances that cause us to publish a final rule more than 3 years after the publication date of the proposed rule. In this case, the complexity of the rule and the scope of the comments received warrant the extension of the timeline for publication. SUMMARY: The timeline for publication of the final is extended for 1 year, until March 1, 2020. FOR FURTHER INFORMATION CONTACT: Frank Whelan, (410) 786–1302. SUPPLEMENTARY INFORMATION: In the March 1, 2016 Federal Register (81 FR 10720), we published a proposed rule titled ‘‘Medicare, Medicaid, and Children’s Health Insurance Programs; Program Integrity Enhancements to the Provider Enrollment Process’’ that would implement sections of the Affordable Care Act that require Medicare, Medicaid, and Children’s Health Insurance Program (CHIP) providers and suppliers to disclose certain current and previous affiliations DATES: ENVIRONMENTAL PROTECTION AGENCY VerDate Sep<11>2014 1697 in the issue of Tuesday, February 5, 2019, make the following correction: On page 1691, in the first column, under the DATES heading, ‘‘February 5, 2019’’ should read ‘‘April 8, 2019’’. Jkt 247001 PO 00000 Frm 00036 Fmt 4702 Sfmt 4702 with other providers and suppliers. This proposed rule would also provide us with additional authority to deny or revoke a provider’s or supplier’s Medicare enrollment. These and other important provisions in the proposed rule would: (1) Eliminate significant program integrity loopholes of longstanding concern to CMS and the Department; and (2) help halt and deter ongoing fraudulent and abusive behavior, including patient harm, in Medicare, Medicaid, and CHIP. Section 1871(a)(3)(A) of the Act requires the Secretary of the Department of Health and Human Services, in consultation with the Director of the Office of Management and Budget (OMB), to establish a regular timeline for the publication of a final rule based on the previous publication of a proposed rule or an interim final rule. Section 1871(a)(3)(B) of the Act allows the timeline for publishing Medicare final regulations to vary based on the complexity of the regulation, the number and scope of comments received, and other related factors. The timeline for publishing the final rule, however, cannot exceed 3 years from the date of publishing the proposed regulation unless there are exceptional circumstances. The Secretary may extend the initial targeted publication date of the final rule if the Secretary provides public notice thereof, including a brief explanation of the justification for the variation, no later than the rule’s previously established proposed publication date. After consultation with the Director of OMB, the Department, through CMS, published a notice in the December 30, 2004 Federal Register (69 FR 78442) establishing a general 3-year timeline for publishing Medicare final rules after the publication of a proposed or interim final rule. Consistent with this, the final rule for the March 1, 2016 proposed rule was to be published by March 1, 2019. This document announces an extension of the timeline for publication of the final rule due to exceptional circumstances. Based on both the public comments received and internal stakeholder feedback, we have determined that more time is needed to address and resolve certain complex policy and operational issues that the commenters and stakeholders raised. We stress that our decision in this matter to extend the timeline for issuing a final rule should not be viewed as a diminution of the Department’s commitment to timely and effective rulemaking. Our goal remains to publish, as expeditiously as feasible, a final rule that strengthens our program integrity efforts while minimizing the E:\FR\FM\28FEP1.SGM 28FEP1

Agencies

[Federal Register Volume 84, Number 40 (Thursday, February 28, 2019)]
[Proposed Rules]
[Page 6740]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: C1-2019-00787]


-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA-HQ-OPP-2017-0418; FRL-9970-24]
RIN 2070-ZA16


Fenoxaprop-ethyl, Flufenpyr-ethyl, Imazapyr, Maleic hydrazide, 
Pyrazon, Quinclorac, Triflumizole, et al.; Proposed Tolerance and 
Tolerance Exemption Actions

Correction

    In proposed rule document 2019-00787, appearing on pages 1691 
through 1697 in the issue of Tuesday, February 5, 2019, make the 
following correction:
    On page 1691, in the first column, under the DATES heading, 
``February 5, 2019'' should read ``April 8, 2019''.

[FR Doc. C1-2019-00787 Filed 2-27-19; 8:45 am]
 BILLING CODE 1301-00-D